Here’s whether Akebia Therapeutics, Inc. (AKBA) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Caution.
🟡
Caution
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.94% over 10 days); RSI 43 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -41.4%. Currently 65.7% off its 52-week high. Score: +0/7.
AKBA is trading below its 200-day MA ($2.10) — a key warning sign the longer-term trend is under pressure. An RSI of 43.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -41.4% compares to +24.4% for SPY (trailed the market by 65.8%). The current 65.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $5,858 today
vs. S&P 500 (SPY) — same period trailed market by 65.8%